Top of this page
Skip navigation, go straight to the content
Sitemap
-
About UCB
-
UCB Worldwide
-
UCB Worldwide
- Australia & New Zealand
- Austria
- Belgium & Luxembourg
- Bulgaria
- Canada
- China
- Czech Republic
- Denmark
- Egypt
- Finland
- France
- Germany
- Greece
- Headquarters
- Hungary
- India
- Ireland
- Italy
- Japan
- Kazachstan
- Korea
- Mexico & Latin America
- Norway
- Poland
- Portugal
- Romania
- Russia (+CIS)
- Slovak Republic
- Spain
- Sweden
- Switzerland
- The Netherlands
- Turkey
- Ukraine
- United Kingdom
- U.S.A.
-
UCB Worldwide
-
Investors
- Overview
- UCB in Brief
- Shares
- Financials
- Annual Reports
- Corporate Governance
- Presentations
- News
- Calendar
- Magazine
-
Job Seekers
-
Magazine
-
Media Room
-
Partners
-
Patients
-
Products
-
R & D
- Overview
- Pipeline
- Science-technologies
- Info centre
- Clinical trials
- Partnerships
- People
- Glossary
-
Post-Doc programme
-
Project details and how to apply
- Autoimmune disease and immunological tolerance
- Novel antibody based biological therapeutic target discovery for the treatment of immunological diseases
- Innovative technology platforms to expand drug discovery in epilepsy
- Investigating transporters and related protein in CNS diseases
- Novel applications of communications theories in rational drug design
- The biology of the bone regulatory protein sclerostin
- Development of drug discovery enabling mass spectrometric technologies
- An investigation into the early role of macrophages in metabolic syndrome
- Identification of MicroRNAs (miRNAs) small molecules ligands using biology-oriented synthesis
- Investigating the role of the pathophysiological pathways involved in the progression of Parkinson’s disease
- Identification of targets for the treatment of Parkinson's and Alzheimer's Disease
- UCB's publications
- Post-doctoral programme flyer
-
Project details and how to apply
- Magazine
